Compare APWC & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APWC | ENTX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | Taiwan | Israel |
| Employees | 1175 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.4M | 58.2M |
| IPO Year | 1997 | 2015 |
| Metric | APWC | ENTX |
|---|---|---|
| Price | $1.58 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 26.8K | ★ 259.3K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $12.60 | $30.43 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.27 | $0.91 |
| 52 Week High | $2.34 | $3.22 |
| Indicator | APWC | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 71.50 |
| Support Level | $1.30 | $1.48 |
| Resistance Level | $1.64 | $2.27 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 45.83 | 83.80 |
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, the PRC, Hong Kong, and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery, and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and the rest of the World.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.